Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Assets (2021 - 2025)

Stoke Therapeutics has reported Assets over the past 5 years, most recently at $418.4 million for Q4 2025.

  • For Q4 2025, Assets rose 54.09% year-over-year to $418.4 million; the TTM value through Dec 2025 reached $418.4 million, up 54.09%, while the annual FY2025 figure was $418.4 million, 54.09% up from the prior year.
  • Assets for Q4 2025 was $418.4 million at Stoke Therapeutics, up from $360.3 million in the prior quarter.
  • Over five years, Assets peaked at $418.4 million in Q4 2025 and troughed at $205.2 million in Q1 2024.
  • A 5-year average of $296.8 million and a median of $281.8 million in 2023 define the central range for Assets.
  • Biggest five-year swings in Assets: decreased 27.19% in 2024 and later skyrocketed 98.31% in 2025.
  • Year by year, Assets stood at $238.9 million in 2021, then grew by 7.2% to $256.1 million in 2022, then dropped by 10.83% to $228.3 million in 2023, then increased by 18.92% to $271.6 million in 2024, then skyrocketed by 54.09% to $418.4 million in 2025.
  • Business Quant data shows Assets for STOK at $418.4 million in Q4 2025, $360.3 million in Q3 2025, and $384.5 million in Q2 2025.